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Midbrain dopamine neurons sustain 
inhibitory transmission using plasma 
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Abstract Synaptic transmission between midbrain dopamine neurons and target neurons in the 
striatum is essential for the selection and reinforcement of movements. Recent evidence indicates 
that nigrostriatal dopamine neurons inhibit striatal projection neurons by releasing a neurotransmitter 
that activates GABAA receptors. Here, we demonstrate that this phenomenon extends to 
mesolimbic afferents, and confirm that the released neurotransmitter is GABA. However, the GABA 
synthetic enzymes GAD65 and GAD67 are not detected in midbrain dopamine neurons. Instead, 
these cells express the membrane GABA transporters mGAT1 (Slc6a1) and mGAT4 (Slc6a11) and 
inhibition of these transporters prevents GABA co-release. These findings therefore indicate that 
GABA co-release is a general feature of midbrain dopaminergic neurons that relies on GABA uptake 
from the extracellular milieu as opposed to de novo synthesis. This atypical mechanism may confer 
dopaminergic neurons the flexibility to differentially control GABAergic transmission in a target-
dependent manner across their extensive axonal arbors.
DOI: 10.7554/eLife.01936.001
Introduction
Dopamine (DA)-releasing neurons in the mammalian midbrain play an important role in fundamental 
behaviors, including motivation, reinforcement learning and motor control, and their dysfunction is 
associated with a wide range of neuropsychiatric disorders (Wise, 2004; Costa, 2007; Schultz, 2007; 
Morris et al., 2009; Redgrave et al., 2010). The major target of midbrain DA neurons is the striatum, 
a large subcortical structure implicated in the selection and reinforcement of motor actions. DA neu-
rons located in the substantia nigra pars compacta (SNc) project mainly to the dorsal striatum (also 
known as the caudate and putamen, CPu), whereas those in the ventral tegmental area (VTA) innervate 
the ventral striatum (or nucleus accumbens, NAc), forming the nigrostriatal and mesolimbic pathways, 
respectively. The striatum controls motor behavior through two parallel output streams with opposing 
effects; the so-called ‘direct’ and ‘indirect’ pathways. Each pathway arises from distinct groups of 
GABAergic striatal projection neurons (SPNs) that differ, amongst other things, in their response to DA 
(Gerfen and Surmeier, 2011; Tritsch and Sabatini, 2012). By providing DA to the striatum, SNc and 
VTA neurons are believed to play a pivotal role in balancing the activity of direct- and indirect-pathway 
SPNs. However, our understanding of the cellular and molecular mechanisms employed by DA neu-
rons to modulate striatal function remains incomplete.
Although the activation of metabotropic receptors following the release of DA from SNc/VTA neu-
rons is undoubtedly central to their function, DA neurons also co-release several other transmitters 
that shape striatal output (Hnasko et al., 2010; Stuber et al., 2010; Tecuapetla et al., 2010; Tritsch 
et al., 2012). In particular, we recently showed that DA neurons in SNc potently inhibit action potential 
firing in SPNs by releasing a transmitter that activates GABAA receptors (Tritsch et al., 2012). Release 
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of this neurotransmitter requires activity of the vesicular monoamine transporter Slc18a2 (VMAT2), 
which can be replaced by exogenous expression of the vesicular GABA transporter Slc32a1 (also 
known as VGAT or VIAAT). In addition, VMAT2 expression in SPNs lacking VGAT is sufficient to sustain 
GABAergic transmission. Collectively, these findings suggest that SNc neurons co-release GABA using 
VMAT2 for vesicular loading. However, this study raises several important questions. First, does 
GABAergic transmission generalize to DA neurons in the VTA, or is it limited to nigrostriatal afferents? 
Second, what is the identity of the transmitter released by DA neurons? GABA exists as a zwitterion at 
neutral pH and lacks the characteristic molecular structure of VMAT2 substrates, which typically fea-
ture an aromatic ring and a positive charge (Yelin and Schuldiner, 1995). GABAA receptors can be 
activated by several naturally-occurring agonists and allosteric modulators, including β-alanine, tau-
rine, imidazole-4-acetic acid and neurosteroids (Johnston, 1996;  Belelli and Lambert, 2005). 
Although none of these molecules constitute ideal candidates for VMAT2-dependent vesicular trans-
port based on their structure, charge, or both, they nonetheless raise the possibility that DA neurons 
liberate a transmitter other than GABA to inhibit SPNs. Third, do all DA neurons contribute to 
GABAergic signaling, or is it reserved to a subpopulation of cells, similar to glutamate co-release from 
DA neurons (Hnasko and Edwards, 2011). Finally, how is inhibitory synaptic transmission sustained in 
DA neurons? Addressing this point will help identify molecules required for GABAergic transmission 
by DA neurons and will permit the development of genetic tools to determine the relative contribution 
of SPN inhibition by DA neurons in vivo under normal and pathological conditions.
In this study, we address these questions by examining the cellular and molecular mechanisms that 
underlie the rapid GABAA receptor-mediated inhibition of SPNs upon stimulation of DA axons. Our 
results provide strong evidence that the inhibitory transmitter released by midbrain DA neurons is 
GABA, and suggest that GABA co-release is a general feature of all midbrain DA neurons. Moreover, 
we reveal that DA neurons rely on GABA uptake through the plasma membrane—but not on de novo 
GABA synthesis—to sustain GABAergic transmission.
Results
Stimulation of mesolimbic axons evokes inhibitory currents in striatal 
projection neurons
We recently reported that activation of SNc axons in dorsal striatum evokes monosynaptic,   
GABAA receptor-mediated inhibitory postsynaptic currents (IPSCs) in SPNs (Tritsch et al., 2012; 
eLife digest The electrical signals that are fired along neurons cannot be transmitted across the 
small gaps, called synapses that are found between neurons. Instead, the neuron sending the signal 
releases chemicals called neurotransmitters into the synapse. These neurotransmitters bind to 
receptor proteins on the surface of the second neuron and control how it fires.
A neurotransmitter called dopamine plays a key role in the circuits of the brain that control how 
we learn certain tasks involving movement. In particular, two populations of neurons from the 
midbrain that release dopamine target the striatum, an area of the brain that is responsible for 
motor control. These neurons also release other neurotransmitters, but the identity of these other 
chemicals is not known, and the details of the interaction between the neurons and the striatum are 
poorly understood.
Previous research showed that some of the midbrain neurons activate receptors that normally 
respond to a neurotransmitter called gamma-aminobutyric acid (GABA). However, several different 
chemicals can trigger this receptor. Using a range of techniques, Tritsch et al. now confirm that 
dopamine neurons release GABA alongside dopamine, and that this applies to both sets of the 
dopamine-producing neurons that feed into the striatum.
Some neurons can manufacture GABA from amino acids found in their internal fluid. However, 
Tritsch et al. could not detect the enzymes needed for this reaction in dopamine-producing neurons. 
Instead, these neurons contain proteins that can transport GABA across the cell membrane, which 
suggests that the neurons collect GABA from the extracellular fluid that surrounds them.
DOI: 10.7554/eLife.01936.002Neuroscience
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Figure 1—figure supplement 1). To determine whether this GABAergic signaling extends to DA neu-
rons projecting to ventral striatum, we expressed channelrhodopsin 2 (ChR2) in the VTA using one of 
two approaches (‘Materials and methods’). We either injected Slc6a3-ires-Cre mice (Backman et al., 
2006) stereotaxically with an adeno-associated virus expressing Cre recombinase-dependent ChR2 
(Figure 1A) or drove ChR2 expression genetically by crossing Slc6a3-ires-Cre mice to transgenic mice 
(Madisen et al., 2012) containing a conditional allele of ChR2 in the Rosa26 locus (Figure 1D). Mice 
also harbored Drd2-Egfp or Drd1a-tdTomato bacterial artificial chromosome (BAC) transgenes to per-
mit distinction between direct- and indirect-pathway SPNs, respectively (Gong et al., 2003; Ade 
et al., 2011). We performed whole-cell voltage-clamp recordings from SPNs in sagittal brain slices of 
NAc in the presence of inhibitors of ionotropic glutamate receptors (NBQX and R-CPP) and metabo-
tropic GABAB receptors (CGP55845) to prevent excitatory synaptic transmission by dopaminergic 
axons, as well as modulatory effects of GABAB receptors, respectively. Under our recording condi-
tions, optogenetic stimulation of VTA axons with brief (1 ms) flashes of blue light reliably evoked 
inward IPSCs in direct- and indirect-pathway SPNs that were blocked by the GABAA receptor antago-
nists picrotoxin (n = 12; Figure 1B,E) and SR95531 (n = 4, not shown). With the exception of synaptic 
latency, optogenetically-evoked IPSCs (oIPSCs) exhibited similar properties in both experimental 
systems and were consequently pooled for analysis. They averaged 353 ± 60 pA in peak amplitude 
(range = 68–905 pA; n = 16) and their kinetics were similar to those observed in dorsal striatum 
(Tritsch et al., 2012; Figure 1—figure supplement 1), with a 10–90% rise time of 2.4 ± 0.2 ms and 
a decay time constant of 46.8 ± 7.2 ms. The synaptic latency of oIPSCs in NAc did not differ from that 
Figure 1. Stimulation of VTA axons evokes GABAergic currents in nucleus accumbens SPNs. ChR2 was expressed 
in VTA DA neurons virally (A–C) or genetically (D–F). (A) Coronal cross section of a Slc6a3-ires-Cre mouse  
ventral midbrain immunolabeled for TH (red) showing viral transduction of ChR2-EYFP in the VTA (green).  
(B) Representative oIPSC recorded from an indirect-pathway SPN in NAc before (black trace) and after (gray trace) 
bath application of the GABAA receptor antagonist picrotoxin (100 μM). Blue line depicts a 1-ms full field flash of 
473 nm laser light (5 mW·mm−2). All recordings in this and subsequent figures were performed at −70 mV using a 
high Cl−internal solution in the presence of NBQX (10 μM), R-CPP (10 μM), and CGP55845 (2–5 μM) in the perfusate. 
(C) Latency from flash onset to oIPSC onset in NAc and dorsal striatum (Caudate/Putamen, CPu) SPNs. For analysis 
of oIPSCs in CPu, ChR2 was expressed in SNc in a separate cohort of mice. White circles depict individual 
recordings, red circles are mean ± SEM. (D–F) As in (A–C) for recordings in Slc6a3-ires-Cre;Ai32 mice. Note that the 
synaptic latency in these mice is significantly longer than in virally transduced Slc6a3-ires-Cre mice in both CPu and 
NAc (p<0.001, Mann–Whitney test), presumably because of lower ChR2 expression in Ai32 mice.
DOI: 10.7554/eLife.01936.003
The following figure supplements are available for figure 1:
Figure supplement 1. Properties of DA neuron oIPSCs in dorsal striatum. 
DOI: 10.7554/eLife.01936.004Neuroscience
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observed in dorsal striatum under similar experimental conditions (Figure 1C,F), indicating that the 
connection is monosynaptic. Synaptic stimulation of midbrain DA neurons therefore directly engages 
GABAA receptors on SPNs in both dorsal and ventral striatum.
Dopaminergic IPSCs are shaped by membrane GABA transporters
The chemical identity of a synaptic neurotransmitter is traditionally established by determining whether 
a synapse fulfills several necessary criteria. They include the presence of (1) presynaptic synthetic 
enzymes, (2) presynaptic vesicular transporters, (3) postsynaptic receptors, and (4) a biochemical 
mechanism for inactivation. In the case of GABAergic signaling at dopaminergic synapses, conditions 
2 and 3 are respectively satisfied by the presence of VMAT2 in DA neurons and GABAA receptors in 
SPNs. For many central nervous system transmitters, condition 4 is mediated by diffusion and reuptake 
through plasma membrane transporters. Of the four genes identified in mice that encode high affinity 
membrane GABA transporters, Slc6a1 is expressed predominantly throughout the brain (Borden, 
1996; Lein et al., 2007). Its gene product, mGAT1, distributes mainly to presynaptic terminals of 
GABAergic neurons and serves to shape the amplitude and time course of IPSCs as well as regulate 
extrasynaptic levels of GABA (Isaacson et al., 1993; Jensen et al., 2003; Overstreet and Westbrook, 
2003; Conti et al., 2004; Chiu et al., 2005; Bragina et al., 2008; Kirmse et al., 2008; Cepeda et al., 
2013). Importantly, mGAT1 is highly selective for GABA and does not transport structurally similar 
GABAA receptor agonists such as β-alanine, taurine, and muscimol (Johnston et al., 1978; Tamura 
et al., 1995). Thus, we reasoned that if dopaminergic IPSCs are modulated by inhibition of mGAT1, 
it would provide compelling evidence that GABA is the neurotransmitter released.
To test this, we recorded dopaminergic oIPSCs from SPNs in dorsal striatum (Figure 2). Stimulation 
intensity was calibrated to evoke sub-maximal IPSCs (approximately 20% of IPSC peak amplitude at 
maximum intensity; mean: 232 ± 40 pA, n = 19) in order to minimize spillover of GABA at dopamin-
ergic synapses (Figure 2—figure supplement 1). We compared the amplitude and kinetics of IPSCs 
recorded before (baseline) and during the first 3–4 min following bath application of control saline 
(ACSF; n = 9; Figure 2A) or saline containing SKF 89976A, a selective mGAT1 antagonist (n = 10; 
Figure 2B). In both conditions, the IPSC amplitude progressively declined to ∼70% of baseline (p<0.01 
each, Wilcoxon signed-rank test; Figure 2C), whereas the synaptic latency and 10–90% rise time 
remained unchanged relative to baseline (p>0.1, Wilcoxon signed-rank test). The decrease in ampli-
tude is consistent with previous reports of activity-dependent rundown of GABA and DA release from 
midbrain DA neurons in vitro (Schmitz et al., 2003; Tritsch et al., 2012; Ishikawa et al., 2013) and 
did not differ between conditions (p=0.8, Mann–Whitney test; Figure 2C, Figure 1—figure supple-
ment 1G), indicating that acute inhibition of mGAT1 does not interfere with neurotransmitter release or 
postsynaptic GABAA receptors. By contrast, mGAT1 antagonism significantly affected decay kinetics: 
whereas oIPSC decay time constants remained stable in control recordings (baseline: 33.6 ± 5.8 ms; 
3–4 min after ACSF wash-in: 32.1 ± 5.8 ms; p=0.6, Wilcoxon signed-rank test), they were prolonged 
by a factor of 3 in the presence of SKF 89976A (baseline: 38.6 ± 6.0 ms; 3–4 min after SKF 89976A 
wash-in: 115.9 ± 26.3 ms; p=0.002, Wilcoxon signed-rank test; Figure 2D). These results indicate that 
mGAT1 activity normally shortens the duration of dopaminergic IPSCs, likely by clearing released neu-
rotransmitter from the extracellular space.
In the striatum, mGAT1 controls ambient levels of GABA that evoke a tonic GABAA receptor-
mediated conductance in SPNs (Ade et al., 2008; Kirmse et al., 2008; Santhakumar et al., 2010; 
Cepeda et al., 2013). Consistent with this, acute pharmacological inhibition of mGAT1 was accom-
panied by a significant increase in holding current caused by a threefold increase in tonic GABA 
current in both direct- and indirect-pathway SPNs (Figure 2—figure supplement 2). To exclude the 
possibility that the increase in oIPSC decay time constant stems from changes in recording condi-
tions during bath application of SKF 89976A, we also monitored spontaneous (s) IPSCs as well as 
IPSCs evoked electrically within the striatum (eIPSCs; Figure 3). Unlike dopaminergic oIPSCs, neither 
the amplitude nor the kinetics of eIPSCs were significantly affected after acute mGAT1 inhibition 
(baseline amplitude: 304 ± 70 pA; 3–4 min after SKF 89976A wash-in: 339 ± 80 pA. Baseline 10–90% 
rise time: 1.3 ± 0.4 ms; 3–4 min after SKF 89976A wash-in: 1.3 ± 0.4 ms. Baseline decay time constant: 
14.8 ± 2.6 ms; 3–4 min after SKF 89976A wash-in: 19.6 ± 4.9 ms; n = 9; p>0.1 for all, Wilcoxon signed-
rank test; Figure 3A,B), despite a notable increase in holding current during the first few minutes 
following bath application of SKF 89976A (baseline: −82 ± 16 pA; SKF 89976A: −143 ± 21 pA; n = 9; 
p<0.001, Wilcoxon signed-rank test). Moreover, although the amplitude of sIPSCs decreased slightly Neuroscience
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Figure 2. The decay kinetics of dopaminergic IPSCs 
are shaped by membrane GABA transporters. (A) Two 
representative oIPSCs recorded in SPNs using 
sub-maximal ChR2 stimulation (1ms; 0.3–2 mW·mm−2; 
blue line) before (baseline, left black trace) and  
3–4 min after (middle gray trace) bath application of 
control saline (ACSF). Right, overlay of peak-normalized 
oIPSCs showing identical decay kinetics. (B) As in (A) 
for oIPSCs recorded in SKF 89976A (10 μM, in green). 
(C) Histogram of mean (±SEM) peak oIPSC amplitude 
normalized to baseline for SPNs perfused in ACSF 
(gray) and SKF 89976A (green). Number of recordings 
indicated in parentheses. (D) Plot of individual 
oIPSC decay time constants before and after bath 
application of ACSF and SKF 89976A. Mean (±SEM) 
shown in red. *p=0.002 vs baseline, Wilcoxon 
signed-rank test.
DOI: 10.7554/eLife.01936.005
The following figure supplements are available for 
figure 2:
Figure supplement 1. oIPSC decay time constant 
increases with stimulus strength. 
DOI: 10.7554/eLife.01936.006
Figure supplement 2. mGAT1 controls ambient levels 
of GABA in the striatum. 
DOI: 10.7554/eLife.01936.007
in SKF 89976A relative to baseline (97 ± 9 vs 83 ± 
7 pA, n = 14; p=0.01, Wilcoxon signed-rank test), 
the frequency and kinetics of sIPSCs remained 
unchanged (baseline frequency: 2.7 ± 0.5 Hz; 
3–4 min after SKF 89976A wash-in: 2.5 ± 0.5 Hz. 
Baseline 10–90% rise time: 0.9 ± 0.1 ms; 3–4 min 
after SKF 89976A wash-in: 0.8 ± 0.1 ms. Baseline 
decay time constant: 6.8 ± 0.4 ms; 3–4 min after 
SKF 89976A wash-in: 6.4 ± 0.5 ms; p>0.05 for all, 
Wilcoxon signed-rank test; Figure 3C,D). These 
results are consistent with previous reports in the 
striatum and hippocampus (Isaacson et al., 1993; 
Kirmse et al., 2008). Thus, our results indicate 
that prolongation of light-evoked IPSCs by SKF 
89976A is specific to dopaminergic synapses 
and not secondary to increased GABAergic tone. 
Together, these data reveal that the duration of 
dopaminergic IPSCs is critically dependent on 
mGAT1 function and, therefore, strongly support 
that GABA is the transmitter co-released by DA 
neurons.
Mouse midbrain DA neurons do 
not express GABA synthetic 
enzymes
Previous reports indicate that up to 10% of mid-
brain DA neurons in rat contain detectable levels 
of mRNA for the 65 kDa isoform of glutamic acid 
decarboxylase (GAD65) (Gonzalez-Hernandez 
et al., 2001; 2004). Together with GAD67, these 
enzymes constitute the major biosynthetic path-
way for GABA in the central nervous system 
(Soghomonian and Martin, 1998). To determine 
the fraction of midbrain DA neurons capable of 
synthesizing (and by extension releasing) GABA 
in mice, we performed double fluorescence   
in situ hybridization for Slc18a2 (Vmat2) and 
Gad1 or Gad2 (which encode GAD67 and GAD65, 
respectively). We focused our analyses to regions 
highlighted in Figure 4A, which consist of the 
SNc and lateral VTA. In agreement with previous 
findings (Gonzalez-Hernandez et al., 2001, 
2004), we did not detect significant overlap 
between Vmat2 and Gad1, as only 4 out of 958 
Vmat2+ neurons (0.4%) showed weak signal for 
Gad1 in SNc and lateral VTA (Figure 4A,B). To our 
surprise, we were also unable to detect Gad2 
mRNA in these regions (Figure 4D,E): only 7 out 
of 1200 Vmat2+ cells (0.6%) were weakly Gad2+, 
despite the presence of numerous brightly-
labeled GABAergic neurons in neighboring sub-
stantia nigra pars reticulata (SNr) and within the 
SNc and lateral VTA. We confirmed our ability   
to detect co-labeling by examining the histaminergic tuberomamillary nucleus (TMN) and dopa-
minergic A13 cell group (Figure 4C,F), both of which express GADs (Lin et al., 1990; Esclapez   
et al., 1993).Neuroscience
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Levels of mRNA for GAD65 and GAD67 in DA neurons may be below the detection threshold, yet 
high enough to sustain GABA synthesis. To address this concern, we attempted to directly visualize 
GAD protein in DA neurons by immunofluorescence using antibodies directed against GAD65/67 and 
tyrosine hydroxylase (TH) to label catecholaminergic neurons. However, the high density of GABAergic 
axons converging into the substantia nigra, combined with the low concentration of GADs in cell 
bodies compared to axon terminals prevented us from clearly identifying DA neurons that expressed 
GADs (not shown). We instead imaged coronal brain sections from knock-in mice (Tamamaki et al., 
2003; Taniguchi et al., 2011) expressing either EGFP or Cre recombinase under transcriptional con-
trol of the endogenous promoter for Gad1 or Gad2 (Figure 5). Cre expression was visualized using a 
sensitive fluorescent reporter allele (Madisen et al., 2010) and TH expression was revealed via immu-
nofluorescence. These mice offer the advantage of having bright somatic labeling including, in the 
case of Gad2-ires-Cre mice, of cells with very little transcriptional activity. However, we were unable to 
detect any DA neuron expressing fluorescent reporter protein driven by either Gad1 (0 out of 519 TH+ 
neurons) or Gad2 (0 out of 526 TH+ neurons) promoters (Figure 5A–D). Collectively, these results indi-
cate that midbrain DA neurons in the SNc and lateral VTA of mice do not express the GABA synthetic 
enzymes GAD65 and GAD67.
Midbrain DA neurons express GABA transaminase
Mammalian cells possess alternative means of synthesizing GABA (Seiler, 1980; Caron et al., 1987; 
Petroff, 2002). GABA transaminase is an enzyme expressed at high levels in GABAergic neurons, 
including in the ventral midbrain that can reversibly convert succinate semialdehyde into GABA, 
Figure 3. The decay kinetics of electrically-evoked and spontaneous IPSCs are insensitive to mGAT1 inhibition. 
(A) Representative electrically-evoked IPSC before (baseline, black trace) and 3–4 min after (green trace) bath 
application of SKF 89976A (10 μM). Inset, overlay of peak-normalized eIPSCs. (B) Plot of individual eIPSC decay 
time constants before (black) and after (green) SKF 89976A application. Mean (±SEM) shown in red. (C and D) As in 
(A and B) for spontaneous IPSCs. Note that sIPSCs have much faster kinetics compared to eIPSCs.
DOI: 10.7554/eLife.01936.008Neuroscience
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and vice versa (Bessman et al., 1953; Roberts and Bregoff, 1953; Medina-Kauwe et al., 1994). 
Because succinate semialdehyde is readily oxidized to succinate to sustain energy production as part 
of the Krebs cycle, GABA transaminase is thought to participate in the degradation of GABA in most 
cells, not its synthesis (Balazs et al., 1970). Nevertheless, we considered the possibility that GABA 
transaminase might contribute GABA in DA neurons. Double fluorescence in situ hybridization for 
Vmat2 and Abat (the gene encoding GABA transaminase) revealed strong co-labeling in 701 out of 
738 DA neurons (95%) within the SNc and lateral VTA (Figure 6A,B), indicating that DA neurons 
express genes involved in GABA metabolism. To test whether DA neurons employ GABA transami-
nase to synthesize GABA, we incubated slices of striatum in control ACSF or vigabatrin (VGT)—an 
irreversible inhibitor of GABA transaminase—for at least thirty minutes prior to recording oIPSCs in 
SPNs. In agreement with prior work (Overstreet and Westbrook, 2001), this manipulation signifi-
cantly elevated extracellular GABA levels (picrotoxin-sensitive tonic current in SPNs in ACSF: 24 ± 3 pA, 
n = 11; in VGT: 115 ± 23 pA, n = 12; p<0.001, Dunn's Multiple Comparison Test), confirming the 
effectiveness of the drug. To minimize differences in light-evoked responses within experiments, 
Figure 4. Midbrain DA neurons do not express Gad1 or Gad2. (A) Two-color in situ hybridization of Slc18a2 (Vmat2; 
top, red) and Gad1 (middle, green) demonstrates the absence of co-labeled DA neurons (bottom) in a coronal 
section through lateral VTA and SNc (dashed outline). Nuclei are stained blue. SNr, substantia nigra pars reticulata; 
D, dorsal; V, ventral; M, medial; L, lateral. (B) Representative high magnification confocal image of Slc18a2 (red) and 
Gad1 (green) expression in SNc. (C) Double fluorescence in situ hybridization for Slc18a2 and Gad1 exhibits 
considerable overlap in the tuberomamillary nucleus (TMN). (D and E) As in (A and B) for Slc18a2 (Vmat2) and Gad2 
expression. (F) Slc18a2 and Gad2 expression co-localize in the A13 dopaminergic cell group.
DOI: 10.7554/eLife.01936.009Neuroscience
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we obtained maximal oIPSCs using strong ChR2 stimulation and limited comparisons to SPNs located 
in similar areas of dorsal striatum in adjacent slices. Under these conditions, we did not detect signifi-
cant differences in oIPSC amplitude between both groups (ACSF: 1.1 ± 0.3 nA; VGT: 1.4 ± 0.2 nA; n 
= 14; p=0.3, Wilcoxon signed-rank test; Figure 6C,D), indicating that GABA transaminase function is 
not required for GABAergic signaling by DA neurons.
Midbrain DA neurons express plasma membrane GABA transporters
Our data indicate that inhibitory synaptic transmission from DA neurons does not depend on synthesis 
of GABA by either GADs or GABA transaminase. In the central nervous system, several synapses rely 
on neurotransmitter reuptake across the plasma membrane as opposed to de novo synthesis to sus-
tain synaptic transmission (Torres et al., 2003; Edwards, 2007). It is therefore conceivable that DA 
neurons inhibit SPNs by releasing GABA they acquire from the extracellular environment. mGAT1 and 
mGAT4 (encoded by Slc6a11) are the two major plasma membrane GABA transporters expressed in 
the mouse midbrain (Borden, 1996; Lein et al., 2007). We therefore performed double fluorescence 
Figure 5. DA neurons in SNc/VTA do not express GAD65 or GAD67. (A) Low magnification epifluorescence image 
of a coronal section through the ventral midbrain showing the absence of overlap between tyrosine hydroxylase 
(TH) immunofluorescence (red) and endogenous EGFP (green) in the SNc and lateral VTA of Gad1-Egfp knock-in 
mice. Blue, nuclear stain. D, dorsal; V, ventral; M, medial; L, lateral. (B) Representative high magnification confocal 
image of SNc in Gad1-Egfp mice showing mutually exclusive expression of EFGP and TH, confirming that GAD67 is 
not expressed in SNc DA neurons. (C and D) As in (A and B) for coronal brain sections from Gad2-ires-Cre knock-in 
mice expressing a fluorescence Cre reporter allele (Ai14). TH immunolabeling and Cre reporter fluorescence 
respectively depicted in red and green for consistency. The absence of overlap indicates that GAD65 is not 
expressed in DA neurons of the SNc and lateral VTA.
DOI: 10.7554/eLife.01936.010Neuroscience
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in situ hybridization for Vmat2 and mGat1 or 
mGat4 to establish whether either isoform is 
present in DA neurons (Figure 7). Surprisingly, 
we found considerable expression of mGat1 
in 667 out of 748 Vmat2+ neurons (89%), par-
ticularly within the SNc. mGat4 localized 
predominantly to glial cells, consistent with 
previous reports (Borden, 1996), although 
faint labeling above background was also 
detected in a substantial fraction (80%) of 
DA neurons in SNc and lateral VTA (568 out 
of 713 Vmat2+ neurons).
GAT function is required for 
dopaminergic IPSCs
The expression of mRNA for mGAT1 and 
mGAT4 in DA neurons raises the possibility 
that DA neurons acquire GABA not through 
de novo synthesis, but rather through plasma 
membrane uptake. Being almost exclusively 
composed of GABAergic neurons, the stri-
atum represents a rich source of extracel-
lular GABA for dopaminergic terminals (Ade 
et al., 2008; Kirmse et al., 2008; Janssen 
et al., 2009;  Santhakumar et al., 2010; 
Cepeda et al., 2013). Inhibition of mGAT1 
for a few minutes does not affect the release 
of GABA from SNc axons (Figure 2C), indi-
cating either that this pharmacological 
manipulation incompletely blocks GABA 
reuptake, or that it is too short to deplete 
presynaptic GABA levels. To determine 
whether uptake of ambient GABA is neces-
sary for sustaining GABAergic transmission 
by DA neurons, we therefore inhibited both 
mGAT1 and mGAT4 in striatal slices using a 
cocktail of SKF 89976A and SNAP-5114   
(a mGAT4 antagonist) for at least 30 min 
prior to examining oIPSCs in SPNs in the 
continued presence of GAT antagonists. 
Whereas oIPSCs obtained under control 
conditions averaged 1.3 ± 0.2 nA in ampli-
tude (n = 15), oIPSCs recorded in adjacent 
slices with GABA transport chronically blocked 
were significantly smaller (0.20 ± 0.07 nA,   
n = 16; p<0.001 vs ACSF, Dunn's Multiple 
Comparison Test; Figure 8A,B). Importantly, 
prolonged exposure to SKF 89976A and 
SNAP-5114 did not prevent transmitter release 
non-specifically, as light-evoked dopamine 
release from SNc axons as well as GABA 
release from striatopallidal terminals were 
maintained under these conditions (Figure 8—
figure supplement 1). Moreover, the small 
picrotoxin-sensitive oIPSCs that remained 
exhibited extremely long decay time constants 
Figure 6. GABA transaminase is not required for GABA 
release by DA neurons. (A) Double fluorescence in situ 
hybridization for Slc18a2 (Vmat2; red) and Abat (green) 
reveals that midbrain DA neurons overwhelmingly express 
GABA transaminase. Blue, nuclear stain. D, dorsal; V, ventral; 
M, medial; L, lateral. (B) High magnification confocal image 
of Slc18a2 (red) and Abat (green) mRNA distribution in SNc. 
(C) Light-evoked IPSCs recorded from SPNs upon strong 
ChR2 stimulation (1 ms, 5 mW·mm−2; blue line) after 
prolonged incubation in ACSF (black) or vigabatrin (VGT,  
100 μM; magenta). (D) Plot of mean peak oIPSC amplitude 
in SPNs recorded in similar regions of dorsal striatum in 
adjacent slices (depicted by gray lines) incubated in either 
ACSF (black) or VGT (magenta). Mean (±SEM) values for 
each group shown in red.
DOI: 10.7554/eLife.01936.011Neuroscience
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(>1.5 s), consistent with persistent GABAergic signaling in the absence of plasma membrane 
reuptake.
Chronic inhibition of GABA reuptake was also accompanied by considerable elevation of ambient 
GABA in the striatum, as evidenced by a 7.5-fold increase in tonic GABAA receptor-mediated current 
in SPNs (picrotoxin-evoked tonic current in ACSF: 24 ± 3 pA, n = 11; in GAT antagonists: 182 ± 32 pA, 
n = 11; p<0.001, Dunn's Multiple Comparison Test; Figure 8C). This increase in extracellular GABA 
might account for the reduced amplitude of oIPSCs by promoting the desensitization of GABAA recep-
tors, by shunting synaptic currents, or both. To examine these possibilities, we included an additional 
experimental condition in which slices were pre-incubated in muscimol before evoking dopaminergic 
oIPSCs (Figure 8A,B). Muscimol is a potent synaptic and extrasynaptic GABAA receptor agonist that 
promotes GABAA receptor desensitization to the same extent as GABA (Mortensen et al., 2010), but 
displays minimal affinity for plasma membrane GABA transporters (Johnston et al., 1978). The con-
centration of muscimol was titrated to evoke tonic GABAA receptor-mediated currents similar those 
that developed upon persistent GAT inhibition (picrotoxin-sensitive tonic current: 212 ± 46 pA, n = 10; 
p<0.001 vs ACSF; p>0.05 vs GAT antagonists, Dunn's Multiple Comparison Test; Figure 8C). Strikingly, 
this manipulation did not reduce the amplitude of dopaminergic oIPSCs (1.3 ± 0.3 nA, n = 12; p>0.05 
vs ACSF, p<0.01 vs GAT antagonists, Dunn's Multiple Comparison Test; Figure 8A,B), indicating that 
the reduction in oIPSC amplitude observed following GAT inhibition is not secondary to elevation 
of ambient GABAergic tone. In agreement with this conclusion, the amplitude of oIPSCs was not 
Figure 7. Midbrain DA neurons express plasma membrane GABA transporters. (A) Two color in situ hybridization 
for Slc18a2 (Vmat2; top, red) and mGat1 (middle, green) shows considerable overlap in SNc and lateral VTA 
(bottom). Nuclei are stained blue. D, dorsal; V, ventral; M, medial; L, lateral. (B) Representative high magnification 
confocal image of Slc18a2 (red) and mGat1 (green) in SNc confirms that DA neurons express mRNA for mGAT1.  
(C) Same as (A) for Slc18a2 (top, red) and mGat4 (middle, green). Note that mGat4 is most strongly expressed in 
star-shaped glial cells. (D) Confocal image through SNc reveals strong expression of mGat4 mRNA in glial cells and 
weak labeling in DA neurons.
DOI: 10.7554/eLife.01936.012Neuroscience
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diminished by prolonged treatment with VGT 
either (Figure 6C,D), despite significant increases 
in extracellular GABA (picrotoxin-sensitive tonic 
current in VGT: 115 ± 23 pA, n = 12; p<0.01 vs 
ACSF, p>0.05 vs GAT antagonists or muscimol, 
Dunn's Multiple Comparison Test; Figure 8C).
These results collectively indicate that GAT 
function is necessary for GABAergic transmission 
from SNc axons. If membrane GABA reuptake is 
required for supplying GABA for vesicular exocy-
tosis, inhibiting GATs should prevent DA neurons 
from maintaining GABA release with repeated 
stimulation. Indeed, chronic inhibition of GATs pre-
cipitated the rundown of GABAergic transmission 
from DA neurons in an activity-dependent manner 
(Figure 8D, Figure 8—figure supplement 2). A 
second prediction is that elevating extracellular 
GABA should attenuate synaptic rundown. To test 
this, we locally applied GABA (100 μM) to the 
dorsal striatum for 5–10 min prior to recording 
oIPSCs from SPNs. Following this manipulation, 
the amplitude of oIPSCs was maintained for sev-
eral minutes after break-in (Figure 8E). Importantly, 
this increase in oIPSC amplitude by exogenous 
GABA was prevented in slices incubated in GAT 
antagonists (Figure 8E). These data therefore 
provide strong evidence that membrane GABA 
transporters play an important role in sustaining 
GABAergic transmission from DA neurons by sup-
plying the neurotransmitter GABA to presynaptic 
terminals for vesicular loading and exocytosis.
Discussion
Despite the importance of midbrain DA neurons, 
the mechanisms by which they shape the activity 
of target neurons in the striatum remain poorly 
understood. In this study, we combined histo-
chemical and electrophysiological approaches to 
define the cellular and molecular mechanisms that 
govern GABAergic signaling by DA neurons. Our 
findings indicate that the vast majority of midbrain 
DA neurons have the capacity to co-release GABA 
and identify presynaptic membrane GABA trans-
porters as the likely mechanism employed by DA 
neurons to acquire GABA for vesicular exocytosis.
Midbrain DA neurons co-release 
GABA
The chemical identity of a synaptic transmitter is 
typically established only after several independent 
observations converge on a plausible candidate. 
In this case, the transmitter released by midbrain 
DA neurons (1) functions as a GABAA receptor 
agonist, (2) serves as a substrate for VGAT (Tritsch 
et al., 2012), and (3) is a substrate for mGAT1. 
Although VGAT can transport GABA, glycine, and 
Figure 8. Sustained GABAergic signaling from DA 
neurons requires GAT function. (A) Dopaminergic 
IPSCs evoked by strong ChR2 stimulation (1 ms, 5 
mW·mm−2; blue line) in slices incubated for at least  
30 min in control ACSF (left, black), muscimol (0.1 μM; 
right, gray) or a cocktail of mGAT1 and mGAT4 
antagonists (10 μM SKF 89976A + 50 μM SNAP-5114, 
respectively; middle, green). Recordings were 
performed in the continued presence of each drug, in 
addition to the GABAB receptor antagonist CGP55845 
(2–5 μM) and the glutamate receptor blockers NBQX 
(10 μM) and R-CPP (10 μM). Inset, oIPSC in GAT 
antagonists shown on longer time scale to illustrate 
slow kinetics. (B) Plot of peak oIPSC amplitudes 
recorded from individual SPNs in adjacent slices after 
prolonged incubation in ACSF (black), mGAT1 and 
mGAT4 inhibitors (green) and muscimol (gray). Mean 
(±SEM) indicated in red. *p<0.01 for indicated 
comparisons, Dunn's Multiple Comparison Test.  
(C) Histogram of tonic GABA current (IGABA) measured 
in SPNs as the reduction in holding current evoked by 
bath application of the GABAA receptor antagonist 
picrotoxin (100 μM) under control conditions (black),  
or after prolonged incubation in mGAT1 and mGAT4 
blockers (10 μM SKF 89976A + 50 μM SNAP-5114; 
green), muscimol (0.1 μM; gray) or vigabatrin (100 μM; 
magenta). *p<0.01 vs ACSF, Dunn's Multiple Comparison 
Test. Number of recordings indicated in parentheses. 
(D) Plot of consecutive oIPSC amplitudes (normalized 
to the first light-evoked response) over time under 
control conditions (ACSF; black; n = 25) and after 
prolonged incubation in a cocktail of GAT antagonists 
Figure 8. Continued on next pageNeuroscience
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β-alanine into synaptic vesicles (Gasnier, 2000; 
Wojcik et al., 2006; Juge et al., 2013), glycine 
does not function as a GABAA receptor agonist, 
and the low affinity of β-alanine for GABAA recep-
tors would give rise to IPSCs with faster kinetics 
than the ones we observed (Jones et al., 1998a). 
In addition, mGAT1 is highly selective for GABA 
(Borden, 1996), and applying GABA exogenously 
helped sustain IPSCs from DA neurons in a GAT-
dependent fashion. Although we did not detect 
GABA synthetic enzymes in DA neurons in our 
experiments, SNc and VTA neurons display a 
GABAergic phenotype, as they contain mRNA 
for GABA transaminase and the membrane GABA 
transporters mGAT1 and mGAT4. Together, these 
results strongly suggest that the neurotransmitter 
released by midbrain DA neurons is GABA. In agree-
ment with this conclusion, a recent electron micro-
scopic study detected GABA in close association 
with VMAT2-containing synaptic vesicles in dopa-
minergic terminals within striatum (Stensrud et al., 
2013). Moreover, other dopaminergic neurons in the 
central nervous system have been reported to con-
tain and/or release GABA, including amacrine cells in the retina (Hirasawa et al., 2012), periglomeru-
lar cells in the olfactory bulb (Maher and Westbrook, 2008; Borisovska et al., 2013; Liu et al., 2013), 
as well as dopaminergic cell groups throughout the brain (Bjorklund and Dunnett, 2007; Stamatakis 
et al., 2013), suggesting that GABA co-release may be a general property of dopaminergic cells.
Midbrain DA neurons sustain inhibitory transmission using plasma 
membrane uptake of GABA
Synaptic transmission requires constant refilling of new and recycled vesicles, which is contingent upon 
the availability of transmitter in the cytosol. Most GABAergic neurons sustain inhibitory transmission 
by maintaining high cytosolic concentrations of GABA using de novo synthesis from glutamate by 
GAD67 and to a lesser extent GAD65 (Asada et al., 1997; Tian et al., 1999; Petroff, 2002). Given that 
all cells contain glutamate, an amino acid necessary for the production of proteins, the expression of 
either GAD67 or GAD65 in conjunction with a vesicular GABA transporter is sufficient to mediate vesic-
ular release of GABA. Previous reports have estimated that up to 10% of DA neurons in the SNc and 
VTA of rats express mRNA for GAD65 (Gonzalez-Hernandez et al., 2001, 2004), suggesting that GABA 
release may be limited to a subpopulation of DA neurons. We were unable to replicate this observa-
tion using two separate approaches, indicating that DA neurons in the SNc and lateral VTA of mice do 
not rely on de novo synthesis of GABA and have instead adopted other means of obtaining GABA.
Most classical transmitters are transported back into the presynaptic terminal after vesicular release 
using plasma membrane transporters. This process is important not only for limiting the duration of 
synaptic currents and preventing extrasynaptic spillover, but also for replenishing presynaptic trans-
mitter levels (Edwards, 2007; Conti et al., 2011). In fact, several synapses, including monoaminergic 
(Giros et al., 1996; Bengel et al., 1998; Jones et al., 1998b; Xu et al., 2000), glycinergic (Gomeza 
et al., 2003a, 2003b; Rousseau et al., 2008; Apostolides and Trussell, 2013) as well as some 
GABAergic terminals (Mathews and Diamond, 2003; Bak et al., 2006; Fricke et al., 2007; Brown 
and Mathews, 2010; Wang et al., 2013) rely heavily on membrane transporter function to maintain 
cytosolic transmitter pools available for vesicular loading. Our results show that DA neurons contain 
mRNA for mGAT1 and mGAT4, indicating that DA neurons might acquire GABA through membrane 
transport. Indeed, we find that prolonged inhibition of mGAT1 and mGAT4 inhibited GABAergic trans-
mission by DA neurons and precipitated the rundown of oIPSCs, suggesting that DA neurons critically 
depend on extracellular GABA uptake to maintain cytoplasmic GABA levels and fill synaptic vesicles. 
By contrast, application of exogenous GABA helped sustain inhibitory transmission from DA neurons. 
By virtue of the fact that the vast majority of DA neurons in the SNc and lateral VTA contain mRNA for 
(10 μM SKF 89976A + 50 μM SNAP-5114; green; n = 
11). *p<0.001 vs ACSF, Sidak's multiple comparison 
test. (E) As in (D) for slices supplied with exogenous 
GABA (100 μM) for 5–10 min before obtaining oIPSCs 
from SPNs in dorsal striatum (blue; n = 10), and slices 
supplied with exogenous GABA after prolonged 
inhibition of GATs with 10 μM SKF 89976A + 50 μM 
SNAP-5114 (magenta; n = 12). *p<0.05 vs ACSF, 
#p<0.005 vs GABA, Tukey's multiple comparison test. 
Control traces in (D) and (E) are the same as in Figure 
1—figure supplement 1D.
DOI: 10.7554/eLife.01936.013
The following figure supplements are available for 
figure 8:
Figure supplement 1. Chronic GAT block does not 
non-specifically affect synaptic transmission at 
GABAergic and dopaminergic synapses. 
DOI: 10.7554/eLife.01936.014




Tritsch et al. eLife 2014;3:e01936. DOI: 10.7554/eLife.01936  13 of 20
Research article
mGATs, our results suggest that GABA co-release is, unlike glutamate co-transmission (Hnasko and 
Edwards, 2011), a common feature of these cells in the adult nervous system. The reliance on plasma 
membrane uptake may partially explain why release of both DA and GABA from these neurons is 
prone to rundown upon repeated stimulation in brain slices (Schmitz et al., 2003; Tritsch et al., 2012; 
Ishikawa et al., 2013), whereas release of glutamate from dopaminergic neurons or GABA from SPNs 
(which presumably depend on neurotransmitter synthesis to sustain release) do not suffer from the 
same shortcoming (Tritsch et al., 2012; Figure 1—figure supplement 1D). Nevertheless, these find-
ings provide evidence that the expression of GABA synthetic enzymes is not required to sustain 
GABAergic transmission, and identify a GABAergic synapse that instead relies entirely on recycling 
extracellular GABA. Interestingly, a similar mechanism underlies exocytic release of serotonin from 
dopaminergic neurons (Zhou et al., 2005) as well as from glutamatergic thalamocortical neurons 
during development (Lebrand et al., 1996).
Implications of GABAergic signaling for striatal function
Although DA neurons in SNc and VTA differ in the inputs they receive and the signals they convey 
(Matsumoto and Hikosaka, 2009; Lammel et al., 2011, 2012; Watabe-Uchida et al., 2012; Roeper, 
2013), we find that both cell populations are capable of co-releasing GABA with DA, pointing to a 
fundamental property of dopaminergic signaling. Morphological studies of SPNs at the electron 
microscopic level have revealed that the majority of dopaminergic synapses terminate on the neck of 
spines that receive excitatory inputs from cortex and thalamus (Wickens and Arbuthnott, 2005). 
Although the actions of DA are not believed to be spatially localized (Arbuthnott and Wickens, 
2007), this unique synaptic arrangement is indicative of an additional, point-to-point mode of action. 
An intriguing possibility is that GABA co-release may function to hyperpolarize spines or shunt excita-
tory cortical and thalamic inputs by activating GABAA receptors. Phasic activation of DA neurons may 
thereby dampen ongoing cortical and thalamic drive onto SPNs to limit DA receptor-mediated plastic 
changes to synaptic inputs most strongly activated by salient or rewarding stimuli. In addition, the 
mechanism adopted by DA neurons to obtain GABA may confer these cells the flexibility to dynami-
cally and locally control GABAergic transmission across their extensive axonal arbors. For instance, 
VTA neurons projecting to NAc and medial prefrontal cortex may only co-release GABA in the former, 
where extracellular GABA levels are high compared to cortex (Drasbek and Jensen, 2006; Weitlauf 
and Woodward, 2008). Alternatively, phasic and chronic changes in mGAT function or extracellular 
GABA levels resulting from synaptic activity, drugs or disease may alter the amplitude and kinetics of 
GABAergic currents arising from midbrain dopamine neurons. A greater understanding of the relative 
effects of DA and GABA on the activity of striatal circuits will help reveal how DA neurons contribute 
to behavior in health and disease.
Materials and methods
Experimental subjects and stereotaxic surgery
All experimental manipulations were performed in accordance with protocols approved by the 
Harvard Standing Committee on Animal Care following guidelines described in the US National 
Institutes of Health Guide for the Care and Use of Laboratory Animals. All mice were group-housed 
and maintained on a 12-hr light cycle with ad libitum access to food and water. Slc6a3-ires-Cre knock-
in mice expressing Cre recombinase in DA neurons (Backman et al., 2006) were obtained from 
Jackson Labs (Bar Harbor, ME; stock # 006660). These mice were crossed with Drd2-Egfp (GENSAT, 
founder line S118) or Drd1a-tdTomato (stock # 016204; Jackson Labs) BAC transgenic mice to permit 
distinction between direct- and indirect-pathway SPNs (Gong et al., 2003; Ade et al., 2011). To geneti-
cally target indirect pathway SPNs, Adora2a-Cre BAC transgenic mice (GENSAT, founder line KG139) were 
used. For stereotaxic viral injections, postnatal day 18–25 mice were anesthetized with isoflurane, placed in 
a small animal stereotaxic frame (David Kopf Instruments, Tujunga, CA) and injected with 1 μl of an adeno-
associated virus (∼1012 genome copies per ml; UNC Vector Core Facility, Chapel Hill, NC) encoding 
Cre-dependent ChR2 (AAV2/8.EF1α.DIO.hChR2(H134R)-mCherry or AAV2/8.EF1α.DIO.hChR2(H134R)-
EYFP), as described previously (Tritsch et al., 2012). Injection coordinates were 0.8 mm anterior from 
Lambda, 1.3 mm lateral and 4.4 mm below pia for SNc, and 0.8 mm anterior from Lambda, 0.6 mm 
lateral and 4.4 mm below pia for VTA. Alternatively, ChR2(H134R)-EYFP was expressed genetically 
in Cre-containing cells by crossing Slc6a3-ires-Cre;Drd2-Egfp or Slc6a3-ires-Cre;Drd1a-tdTomato mice Neuroscience
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with Ai32 mice (stock # 012569; Jackson Labs) (Madisen et al., 2012). The knock-in lines used in Figure 5 
include Gad1-Egfp (Tamamaki et al., 2003) and Gad2-ires-Cre mice (Taniguchi et al., 2011). The latter 
were crossed with mice bearing a Cre-dependent tdTomato reporter transgene (Ai14; stock # 007914; 
Jackson Labs) to reveal the distribution of Cre+ cells (Madisen et al., 2010). Mice were maintained on a 
C57BL/6 background. Only mice heterozygous for all transgenes were used for experiments.
Immunocytochemistry and in situ hybridization
Mice were anesthetized with isoflurane and transcardially perfused with phosphate buffered saline 
followed by 4% (wt/vol) paraformaldehyde in 0.1 M sodium phosphate buffer. 50-micrometer coronal 
brain sections were subject to immunohistochemical staining for tyrosine hydroxylase (AB152; 1:2000; 
Millipore, Billerica, MA), as described previously (Tritsch et al., 2012). Endogenous tdTomato and EGFP 
fluorescence were not immuno-enhanced. Double fluorescence in situ hybridization was performed 
using a tyramide signal amplification method according to the manufacturer's instructions (NEL753001KT; 
PerkinElmer, Waltham, MA), as previously described (Kwon et al., 2012). Briefly, brains from 4-week old 
mice were dissected and immediately frozen in liquid nitrogen. They were then cut in 25-μm-thick sec-
tions with a cryostat (Leica, Buffalo Grove, IL), postfixed in 4% PFA, acetylated in 1% triethanolamine and 
0.25% acetic anhydride, dehydrated serially in ethanol, bleached in 3% hydrogen peroxide diluted in 
methanol, prehybridized, and hybridized at 65°C using the following anti-sense probes provided by the 
Allen Institute for Brain Science (riboprobe ID specified in parentheses): Gad1 (RP_040324_01_F01), 
Gad2 (RP_071018_02_B07), Vmat2 (RP_071218_02_B08), mouse Gat1 (RP_071204_04_H01), mouse 
Gat4 (RP_050428_04_D04), and Abat (RP_050301_02_C02). For in vitro transcription, each cDNA was 
cloned out from a mouse brain cDNA library using the primer sets suggested in the in situ hybridization 
data portal from the Allen Institute for Brain Science. Two fluorescein- or digoxigenin-labeled riboprobes 
generated by an in vitro transcription method (Promega, Madison, WI) were hybridized simultaneously 
and stained by fluorescein or Cy3 chromogens, respectively. After staining, sections were mounted with 
Prolong Gold antifade reagent with DAPI nuclear stain (Life Technologies, Grand Island, NY).
Slice electrophysiology
Acute brain slices and whole-cell voltage-clamp recordings from identified SPNs were obtained using 
standard methods, as described previously (Tritsch et al., 2012). Briefly, mice (49–178 days old; 
median = 107 days) were anesthetized and perfused with ice-cold artificial cerebrospinal fluid (ACSF) 
containing (in mM) 125 NaCl, 2.5 KCl, 25 NaHCO3, 2 CaCl2, 1 MgCl2, 1.25 NaH2PO4 and 11 glucose 
(295 mOsm·kg−1). Parasagittal slices of striatum (275-μm thick) were subsequently obtained in cold 
choline-based cutting solution (in mM: 110 choline chloride, 25 NaHCO3, 2.5 KCl, 7 MgCl2, 0.5 CaCl2, 
1.25 NaH2PO4, 25 glucose, 11.6 ascorbic acid, and 3.1 pyruvic acid). Following 15 min recovery in 
ACSF at 34°C, slices were kept at room temperature (20–22°C) until use. All solutions were constantly 
bubbled with 95% O2/5% CO2. Whole-cell voltage-clamp recordings were established from direct- and 
indirect-pathway SPNs in dorsal or ventral striatum resting 18–75 μm below the slice surface (median: 
40 μm) in ACSF warmed to 32–34°C. Direct-pathway SPNs were identified as tdTomato+ cells in Drd1a-
tdTomato mice or EGFP–cells in Drd2-EGFP mice, and indirect-pathway SPNs as tdTomato−or EGFP+ 
cells in Drd1a-tdTomato and Drd2-EGFP mice, respectively. Patch pipettes (2–4 MΩ) were filled with 
(in mM) 125 CsCl, 10 TEA-Cl, 10 HEPES, 0.1 Cs-EGTA, 3.3 QX-314 (Cl−salt), 4 Mg-ATP, 0.3 Na-GTP, 
8 Na2-Phosphocreatine (pH 7.3 adjusted with CsOH; 295 mOsm·kg−1). The recording perfusate always 
contained NBQX (10 μM) and R-CPP (10 μM) to block AMPA and NMDA receptor-mediated inward 
currents, respectively, as well as CGP55845 (2–5 μM) to prevent GABAB receptor-evoked pre- and 
post-synaptic modulation. For some experiments (Figures 6 and 8, Figure 8—figure supplements 1 
and 2), slices were incubated for at least 30 min (and up to two hours) in ACSF containing CGP55845 
(2–5 μM) in addition to vigabatrin (100 μM), muscimol (0.1 μM), or SKF 89976A (10 μM) + SNAP-5114 
(50 μM) to allow for the depletion of cytosolic GABA levels and synaptic vesicles containing GABA, 
and to control for the effects of chronically elevated GABAergic signaling. In these cases, drugs con-
tinued to be present in the recording chamber for the duration of the experiment. For Figure 8E, 
GABA (100 μM, in ACSF containing either 5 μM CGP55845 or 5 μM CGP55845 + 10 μM SKF 89976A 
+ 50 μM SNAP-5114) was locally applied to the slice via a gravity-fed 250-μm-wide flow pipe for 
5–10 min prior to recording. For all voltage-clamp experiments, errors due to the voltage drop across 
the series resistance (<20 MΩ) were left uncompensated. Membrane potentials were corrected for a 
∼5-mV liquid junction potential. Under these conditions, GABAA receptor-mediated currents appeared Neuroscience
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inward when SPNs were held at negative membrane potentials (Vhold = −70 mV). To activate ChR2-
expressing fibers, light from a 473-nm laser (Optoengine, Midvale, UT) was focused on the back aperture 
of the microscope objective to produce wide-field illumination of the recorded cell. Brief pulses of 
light (1-ms duration; 5 mW·mm−2 under the objective for maximal stimulation, 0.3–2 mW·mm−2, for 
sub-maximal stimulation) were delivered at the recording site at 30 s intervals under control of the 
acquisition software. Epifluorescence illumination was used sparingly to minimize ChR2 activation prior 
to recording. eIPSCs were evoked using constant-current pulses (0.1 ms, 7–90 μA) delivered every 
15 s through a bipolar tungsten stimulating electrodes positioned within striatum, 100–200 μm 
away from the recorded cell. Constant-potential amperometry was performed as before (Tritsch et al., 
2012) using commercial glass-encased carbon-fiber microelectrodes (Carbostar-1, Kation Scientific, 
Minneapolis, MN) placed within dorsal striatum slices and held at 600 mV. All recordings were obtained 
within 4 hr of slicing. All pharmacological agents were obtained from Tocris (Minneapolis, MN).
Data acquisition and analysis
Brain sections processed for in situ hybridization or immunofluorescence were imaged with an Olympus 
VS110 slide-scanning microscope. High-resolution images of regions of interest were subsequently 
acquired with a Zeiss LSM 510 META confocal microscope (Harvard NeuroDiscovery Center). Individual 
imaging planes were overlaid and quantified for colocalization in ImageJ (NIH) and thresholded for 
display in Photoshop (Adobe). Confocal images in figures represent maximum intensity projections of 
3-µm confocal stacks. Membrane currents were amplified and low-pass filtered at 3 kHz using a 
Multiclamp 700B amplifier (Molecular Devices, Sunnyvale, CA), digitized at 10 kHz and acquired using 
National Instruments acquisition boards and a custom version of ScanImage (Pologruto et al., 2003; 
available upon request or from https://openwiki.janelia.org/wiki/display/ephus/ScanImage) written in 
MATLAB (Mathworks). Electrophysiology data were analyzed offline using Igor Pro (Wavemetrics, Natick, 
MA). In figures, voltage-clamp traces represent the averaged waveform of 3–5 consecutive acquisitions. 
Averaged waveforms were used to obtain current latency, peak amplitude, 10–90% rise time and decay 
time constant. The latter was estimated by measuring the time elapsed from the peak of the IPSC to 1/e 
(36.8%) of the peak amplitude. Detection threshold for sIPSCs was set at 40 pA to facilitate event detec-
tion in the presence of large and noisy tonic GABA currents. For pharmacological analyses in Figures 2 
and 3, the peak amplitude of IPSCs measured 3–4 min following the onset of drug perfusion were aver-
aged, normalized to baseline averages obtained immediately prior to drug application and compared 
statistically to values obtained at corresponding times in control preparations bathed in ACSF. Data 
(reported in text and figures as mean ± SEM) were compared using Prism 6 (GraphPad, La Jolla, CA) with 
the following non-parametric statistical tests (as indicated in the text): Mann–Whitney for group compari-
sons, Wilcoxon signed-rank for paired comparisons, and Kruskal–Wallis analysis of variance (ANOVA) 
followed by Dunn's Multiple Comparison Test for multiple group comparisons. In experiments character-
izing the time course of synaptic transmission rundown, two-way ANOVAs were used followed by the 
Sidak's and Tukey's multiple comparison tests for comparisons between two and more conditions, 
respectively. p values smaller than 0.05 were considered statistically significant. N values represent the 
number of recorded cells. For most experiments, a single cell was recorded from in each slice, with each 
animal contributing fewer than five recordings to individual data sets.
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